Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,163 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,263 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,897)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02658812 | Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT04447014 | Natural History Study of Children and Adults With Adrenocortical Cancer (ACC) | terminated | — | 15 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2023 | clinicaltrials |
| NCT04488263 | Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s | terminated | — | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2023 | clinicaltrials |
| NCT02449681 | Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin | terminated | Phase 2 | 30 | Rain Oncology IncINDUSTRY | 2 | Jan 12, 2023 | clinicaltrials |
| NCT03582618 | CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma | terminated | Phase 2 | 12 | TaiRx, Inc.INDUSTRY | 2 | Jan 10, 2023 | clinicaltrials |
| NCT04088500 | A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma | terminated | Phase 2 | 5 | Bristol-Myers SquibbINDUSTRY | 2 | Jan 10, 2023 | clinicaltrials |
| NCT04044430 | Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer | terminated | Phase 1 | 2 | University of California, San FranciscoOTHER | 1 | Jan 9, 2023 | clinicaltrials |
| NCT02454517 | Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer(PALS) | terminated | N/A | 117 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT02923531 | Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 9 | X4 PharmaceuticalsINDUSTRY | 1 | Dec 29, 2022 | clinicaltrials |
| NCT04147143 | CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study | terminated | — | 56 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT03387514 | Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies(UW17104) | terminated | Phase 2 | 5 | University of Wisconsin, MadisonOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT01433016 | Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI(OBT for HCC) | terminated | Phase 2 | 20 | Meridian Bioscience, Inc.INDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT04453046 | Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | terminated | N/A | 2 | Aethlon Medical Inc.INDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT01381211 | Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)(TRACE) | terminated | Phase 2 | 72 | University Hospital, GhentOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT04642690 | Nitrates and IL-8 in Barrett's Esophagus | terminated | — | 9 | Mayo ClinicOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT03781960 | Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma | terminated | Phase 2 | 7 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05380557 | ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing(ARTEMIS) | terminated | — | 2 | Invitae CorporationINDUSTRY | 1 | Dec 7, 2022 | clinicaltrials |
| NCT03513042 | Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and Neck(ERM-PT-HNSCC) | terminated | — | 12 | Leiden University Medical CenterOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04762225 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma | terminated | Phase 1 | 7 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols. | terminated | — | 22 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04400903 | Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer | terminated | — | 110 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT03506048 | Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer | terminated | Phase 2 | 4 | Emory UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | terminated | Phase 1 | 30 | AmgenINDUSTRY | 5 | Nov 8, 2022 | clinicaltrials |
| NCT02124902 | Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity | terminated | Phase 2 | 148 | Washington University School of MedicineOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT02474173 | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer | terminated | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2022 | clinicaltrials |
| NCT04242173 | Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | terminated | Phase 2 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT01167374 | Carbon Ion Radiotherapy for Hepatocellular Carcinoma(PROMETHEUS-01) | terminated | N/A | 21 | University Hospital HeidelbergOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT03579472 | M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer | terminated | Phase 1 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT01266018 | Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer | terminated | Phase 2 | 22 | Ludwig Institute for Cancer ResearchOTHER | 5 | Oct 25, 2022 | clinicaltrials |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | terminated | Phase 2 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT02415036 | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma | terminated | Phase 2 | 17 | Delcath Systems Inc.INDUSTRY | 1 | Oct 17, 2022 | clinicaltrials |
| NCT05093608 | SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma | terminated | Phase 1 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT00520533 | Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma | terminated | Phase 1 | 8 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT01891695 | OPSCC N0 Nodal Control With Reduced IMRT | terminated | N/A | 1 | Paul W. Read, MDOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04022876 | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) | terminated | Phase 1 | 35 | Aileron Therapeutics, Inc.INDUSTRY | 7 | Oct 10, 2022 | clinicaltrials |
| NCT01727336 | Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma | terminated | Phase 2 | 160 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Oct 6, 2022 | clinicaltrials |
| NCT03781778 | Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors | terminated | Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT03723915 | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | terminated | Phase 2 | 17 | Northwestern UniversityOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT04861948 | IBI188 Combination Therapy in Solid Tumors | terminated | Phase 1 | 9 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Oct 4, 2022 | clinicaltrials |
| NCT01174199 | Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 1 | 13 | Roswell Park Cancer InstituteOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT02943733 | Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs | terminated | Phase 1 | 18 | University of Wisconsin, MadisonOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT04876378 | Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and Hand | terminated | — | 8 | University of California, San FranciscoOTHER | 1 | Sep 9, 2022 | clinicaltrials |
| NCT04985136 | A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) | terminated | Phase 3 | 1 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT02363647 | Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer | terminated | N/A | 10 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | terminated | Phase 1 | 21 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT03945799 | A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence | terminated | Phase 1 / Phase 2 | 28 | Zhejiang UniversityOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT00637624 | N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy(NAC-PNP) | terminated | N/A | 69 | Rijnstate HospitalOTHER | 1 | Aug 25, 2022 | clinicaltrials |
| NCT03750240 | Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy | terminated | N/A | 2 | NYU Langone HealthOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT03998033 | Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma(ET-109) | terminated | Phase 1 | 2 | Eureka Therapeutics Inc.INDUSTRY | 1 | Aug 23, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Jan 25, 2023source: clinicaltrials